DE60100740D1 - Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten - Google Patents

Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten

Info

Publication number
DE60100740D1
DE60100740D1 DE60100740A DE60100740A DE60100740D1 DE 60100740 D1 DE60100740 D1 DE 60100740D1 DE 60100740 A DE60100740 A DE 60100740A DE 60100740 A DE60100740 A DE 60100740A DE 60100740 D1 DE60100740 D1 DE 60100740D1
Authority
DE
Germany
Prior art keywords
peptides
thrombine
derivated
treatment
cardiovascular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60100740A
Other languages
English (en)
Other versions
DE60100740T2 (de
DE60100740T4 (de
Inventor
H Carney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Application granted granted Critical
Publication of DE60100740D1 publication Critical patent/DE60100740D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE60100740A 2000-07-12 2001-07-12 Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten Expired - Lifetime DE60100740D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21758300P 2000-07-12 2000-07-12
PCT/US2001/021944 WO2002004008A2 (en) 2000-07-12 2001-07-12 Methods of therapy with thrombin derived peptides

Publications (1)

Publication Number Publication Date
DE60100740D1 true DE60100740D1 (de) 2003-10-16

Family

ID=22811661

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60100740A Expired - Lifetime DE60100740D1 (de) 2000-07-12 2001-07-12 Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten
DE60100740T Expired - Lifetime DE60100740T4 (de) 2000-07-12 2001-07-12 Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60100740T Expired - Lifetime DE60100740T4 (de) 2000-07-12 2001-07-12 Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten

Country Status (11)

Country Link
US (5) US6867190B2 (de)
EP (1) EP1253937B1 (de)
JP (2) JP3618736B2 (de)
CN (1) CN100500211C (de)
AT (1) ATE249238T1 (de)
AU (2) AU7890701A (de)
CA (1) CA2415778A1 (de)
DE (2) DE60100740D1 (de)
HK (1) HK1060302A1 (de)
TW (1) TWI257307B (de)
WO (1) WO2002004008A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
TWI257307B (en) * 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
AU2002241917B2 (en) * 2000-07-12 2006-06-15 The Board Of Regents, The University Of Texas System Thrombin derived peptides for promoting cardiac tissue repair
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
CA2511223A1 (en) * 2002-01-16 2003-07-31 The Board Of Regents, The University Of Texas System Thrombin derived peptides for promoting cardiac tissue repair
AU2003247848B2 (en) * 2002-07-02 2006-12-21 The Board Of Regents, The University Of Texas System Thrombin peptide derivative dimers
CA2491052A1 (en) * 2002-07-02 2004-02-19 The Board Of Regents, The University Of Texas System Thrombin peptide derivatives
EP1521603B1 (de) * 2002-07-12 2011-01-19 Cook Incorporated Beschichtete medizinische vorrichtung
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
WO2004072235A2 (en) 2003-02-12 2004-08-26 Monsanto Technology Llc Cotton event mon 88913 and compositions and methods for detection thereof
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
WO2005065706A1 (en) 2003-12-31 2005-07-21 Orthologic Corp. Pharmaceutical composition for thrombin peptide derivatives
WO2006023844A2 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
JP2006321740A (ja) * 2005-05-18 2006-11-30 Kanazawa Univ 虚血後血管新生促進剤
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
WO2008036387A2 (en) 2006-09-22 2008-03-27 Orthologic Corp. Method of treating endothelial dysfunction
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
EP2155236A1 (de) * 2007-04-10 2010-02-24 The Board of Regents,The University of Texas System Kombinationstherapie zur herzrevaskularisation und herzreparatur
US8202528B2 (en) * 2007-06-05 2012-06-19 Abbott Cardiovascular Systems Inc. Implantable medical devices with elastomeric block copolymer coatings
GB2450747A (en) * 2007-07-06 2009-01-07 Univ Sheffield Treatment of sensorineural hearing loss
US8586398B2 (en) * 2008-01-18 2013-11-19 Miasole Sodium-incorporation in solar cell substrates and contacts
CA2722621A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
EP2282754A2 (de) * 2008-03-26 2011-02-16 Orthologic Corp. Verfahren zur behandlung von peripherer arterienkrankheit
US20110105400A1 (en) * 2008-03-26 2011-05-05 Orthologic Corp. Methods for treating acute myocardial infarction
US8952129B2 (en) * 2008-03-26 2015-02-10 The Board Of Regents Of The University Of Texas System Method of treating degenerative diseases
WO2010033862A2 (en) * 2008-09-19 2010-03-25 The Board Of Regents, The University Of Texas System Methods for treating cancer
US20130101574A1 (en) * 2010-06-11 2013-04-25 Darrell H. Carney Methods of using thrombin peptide derivatives
GB201314312D0 (en) * 2013-08-09 2013-09-25 Regentec Ltd Composition and delivery system
US20160039876A1 (en) 2014-03-28 2016-02-11 Claresa Levetan Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
CA3135790A1 (en) * 2019-04-12 2020-10-15 Affirmed Pharma, Llc Rusalatide acetate compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5244460A (en) * 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
JPH08508511A (ja) 1993-04-29 1996-09-10 ワシントン・ユニバーシテイー 副行循環の改善への血小板由来成長因子の使用
KR100465222B1 (ko) * 1995-10-24 2005-05-17 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 평활근세포증식억제활성을갖는조직인자응고계인히비터(tfpi)-유래펩티드
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
US6033436A (en) * 1998-02-17 2000-03-07 Md3, Inc. Expandable stent
AU760664B2 (en) 1998-04-17 2003-05-22 Angiogenix, Inc. Therapeutic angiogenic factors and methods for their use
CN1338943A (zh) 1998-10-26 2002-03-06 路德维格癌症研究院 利用vegf－c或vegf－d基因或蛋白预防再狭窄
US6363938B2 (en) * 1998-12-22 2002-04-02 Angiotrax, Inc. Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth
TWI257307B (en) * 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair

Also Published As

Publication number Publication date
CN100500211C (zh) 2009-06-17
AU7890701A (en) 2002-01-21
US6867190B2 (en) 2005-03-15
EP1253937A2 (de) 2002-11-06
WO2002004008A2 (en) 2002-01-17
JP2004502739A (ja) 2004-01-29
TWI257307B (en) 2006-07-01
DE60100740T2 (de) 2004-07-01
US7034001B2 (en) 2006-04-25
US20020061852A1 (en) 2002-05-23
AU2001278907B2 (en) 2004-10-21
JP3618736B2 (ja) 2005-02-09
US20060134167A1 (en) 2006-06-22
ATE249238T1 (de) 2003-09-15
JP2005036007A (ja) 2005-02-10
DE60100740T4 (de) 2005-01-27
US7732411B2 (en) 2010-06-08
EP1253937B1 (de) 2003-09-10
WO2002004008A3 (en) 2002-08-22
US20080131474A1 (en) 2008-06-05
US7214661B2 (en) 2007-05-08
US20020187933A1 (en) 2002-12-12
US20050153884A1 (en) 2005-07-14
HK1060302A1 (en) 2004-08-06
CA2415778A1 (en) 2002-01-17
US6861407B2 (en) 2005-03-01
CN1455678A (zh) 2003-11-12

Similar Documents

Publication Publication Date Title
DE60100740D1 (de) Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten
JP2004502739A5 (de)
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
DE60132343D1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
ATE555782T1 (de) Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
EA200401070A1 (ru) Способы лечения сосудистых заболеваний
IL131021A0 (en) Multiple site delivery of adenoviral vector for the induction of angiogenesis
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
US20140207050A1 (en) Use of local anesthesia and electrical stimulation in peripheral wound treatment
HK1078263A1 (en) Thrombin derived peptides for promoting cardiac tissue repair
DE60227278D1 (de) Pharmazeutische zubereitungen für die behandlung von läsionen der haut und schleimhäute und diese verwendende verfahren und kits
DE69807710T2 (de) Verwendung von Latenz Assoziierten Peptiden in der Herstellung eines Medikaments zur Verbesserung der Wundheilung.
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE461707T1 (de) Pharmazeutische verbindung und methoden zur behandlungen von menschliche karzinome mittels arginin entzug
ATE224187T1 (de) Verfahren zur vorbeugung und behandlung des myokardialen stunnings
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
EA200501846A1 (ru) Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом
SE9902597D0 (sv) New use
DE69904465T2 (de) Therapie von depressionen
EP1143996A4 (de) Methode zur behandlung von chronischen herzerkrankungen
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
SE0200598D0 (sv) Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
ATE234624T1 (de) Zusammensetzungen zur verstärkung der pharmakologischen aktivität von immunosuppressiva
SU1489728A1 (ru) Способ хирургического лечения гипергидроза дистальных отделов голени и тыла стопы

Legal Events

Date Code Title Description
8364 No opposition during term of opposition